Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000187505 | SCV000241099 | likely pathogenic | not provided | 2014-09-17 | criteria provided, single submitter | clinical testing | p.Ser297Arg (AGC>AGG): c.891 C>G in exon 10 of the GABRA1 gene (NM_000806.5). The S297R variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The S297R variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution alters a highly conserved position in the predicted second transmembrane domain of the GABRA1 protein. Additionally, another missense mutation in a nearby residue (K306T) has been reported in association with Dravet syndrome, and other missense mutations in nearby residues (T294I and T295I) have been reported as de novo mutations in individuals with epilepsy, supporting the functional importance of this region of the protein. In silico analysis predicts S297R is probably damaging to the protein structure/function. Therefore, this variant is a strong candidate for a pathogenic mutation, however the possibility that it is a benign variant cannot be excluded. The variant is found in RETT-EPI panel(s). |